EGM
RXRX icon

Engineers Gate Manager’s Recursion Pharmaceuticals RXRX Stock Holding History

Engineers Gate Manager’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-213,839
Closed -$656K – 2551
2026
Q1 		$656K Buy
+213,839
New +$826K 0.01% 1247
2025
Q4 		– Sell
-10,834
Closed -$52.9K – 2476
2025
Q3 		$52.9K Sell
10,834
-83,673
-89% -$439K ﹤0.01% 2055
2025
Q2 		$478K Buy
+94,507
New +$464K 0.01% 1500
2025
Q1 		– Sell
-46,190
Closed -$312K – 2516
2024
Q4 		$312K Sell
46,190
-129,205
-74% -$869K 0.01% 1681
2024
Q3 		$1.16M Buy
175,395
+97,604
+125% +$700K 0.02% 904
2024
Q2 		$583K Buy
77,791
+19,630
+34% +$171K 0.01% 1155
2024
Q1 		$580K Buy
58,161
+46,790
+411% +$521K 0.02% 1124
2023
Q4 		$112K Buy
+11,371
New +$81.1K ﹤0.01% 1760
2022
Q2 		– Sell
-82,120
Closed -$588K – 2212
2022
Q1 		$588K Buy
+82,120
New +$873K 0.02% 974

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Engineers Gate Manager's RXRX Position: Q2 2026 in Review

Engineers Gate Manager sold out of Recursion Pharmaceuticals (RXRX) in Q2 2026, closing a stake of 213,839 shares — an estimated $656K sold.

Engineers Gate Manager first reported a position in RXRX in Q1 2022 and held it in 9 quarters. The position peaked at $1.16M in Q3 2024. 343 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • Engineers Gate Manager reported no remaining Recursion Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Engineers Gate Manager sold 213,839 Recursion Pharmaceuticals shares in Q2 2026, an estimated $656K.
  • Engineers Gate Manager first reported a position in Recursion Pharmaceuticals in Q1 2022 and held it in 9 quarters.
  • Engineers Gate Manager's Recursion Pharmaceuticals position peaked at $1.16M in Q3 2024.
  • 343 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Engineers Gate Manager's 13F filing for Q2 2026, filed 14 Aug 2026.